spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  HoFH 

 HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement
 HSMN NewsFeed - 14 Aug 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Jan 2017
The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Apr 2016
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 Jan 2014
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 9 Sep 2013
Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 25 Oct 2011
Aegerion Pharmaceuticals Appoints Craig E. Fraser as President, U.S.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Jul 2011
Aegerion Pharmaceuticals Announces Appointment of Paul G. Thomas to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2011
Aegerion Pharmaceuticals Appoints Diane L. Tribble, Ph.D., M.M.Sc., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2011
Aegerion Pharmaceuticals Appoints Martha J. Carter as Chief Regulatory Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2010
Impax Laboratories Confirms Patent Challenge Relating to VYTORIN(R), 10 mg/80 mg
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 25 Apr 2008
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jan 2008
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 17 May 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
Biopharmaceuticals
 HSMN NewsFeed - 1 Jun 2006
Isis Pharmaceuticals Receives Orphan Drug Status for ISIS 301012 for the Treatment of Homozygous Familial Hypercholesterolemia
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
HoFH
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.